We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-8.81%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$4.32B
AUM Growth
+$1.17B
Cap. Flow
+$1.47B
Cap. Flow %
33.94%
Top 10 Hldgs %
67.79%
Holding
43
New
10
Increased
9
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$136M
2
HUM icon
Humana
HUM
+$121M
3
CVS icon
CVS Health
CVS
+$84.2M
4
CI icon
Cigna
CI
+$47.8M
5
EVH icon
Evolent Health
EVH
+$45.7M

Top Sells

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$96M
2
SEM
Select Medical
SEM
+$74.1M
3
GMED icon
Globus Medical
GMED
+$73M
4
BAX icon
Baxter International
BAX
+$63.1M
5
UHS icon
Universal Health Services
UHS
+$28.6M

Sector Composition

Rank Sector Weight
1 Healthcare 58.27%
2 Consumer Staples 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$1.47B 33.89%
2,500,000
+1,500,000
+150% +$884M
MDT icon
2
Medtronic
MDT
$112B
$220M 5.08%
2,750,000
– –
VTRS icon
3
Viatris
VTRS
$20.8B
$187M 4.32%
15,000,000
– –
ZBH icon
4
Zimmer Biomet
ZBH
$18.8B
$170M 3.92%
1,605,000
-895,000
-36% -$96M
GSK icon
5
CALL
GSK
GSK
$107B
$169M 3.91%
+5,000,000
New +$180M
HUM icon
6
Humana
HUM
$43.9B
$165M 3.81%
650,000
+450,000
+225% +$121M
PTCT icon
7
PTC Therapeutics
PTCT
$6.18B
$144M 3.34%
3,200,000
-300,000
-9% -$12.8M
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$16.1B
$142M 3.28%
1,150,000
– –
BAX icon
9
Baxter International
BAX
$12.8B
$135M 3.12%
4,625,000
-1,875,000
-29% -$63.1M
CVS icon
10
CVS Health
CVS
$135B
$135M 3.11%
3,000,000
+1,500,000
+100% +$84.2M
PFE icon
11
CALL
Pfizer
PFE
$143B
$133M 3.07%
+5,000,000
New +$136M
PFE icon
12
Pfizer
PFE
$143B
$133M 3.07%
+5,000,000
New +$136M
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.64B
$122M 2.81%
1,000,000
+225,000
+29% +$27.6M
ASND icon
14
Ascendis Pharma A/S
ASND
$16.5B
$110M 2.55%
800,000
+100,000
+14% +$13.1M
GMED icon
15
Globus Medical
GMED
$11.1B
$101M 2.34%
1,225,000
-925,000
-43% -$73M
GSK icon
16
GSK
GSK
$107B
$84.5M 1.96%
2,500,000
-500,000
-17% -$18M
BKD icon
17
Brookdale Senior Living
BKD
$3.55B
$70.1M 1.62%
13,935,000
– –
CON
18
Concentra Group Holdings
CON
$4.04B
$69.2M 1.6%
3,500,000
+1,525,000
+77% +$31.5M
QGEN icon
19
Qiagen
QGEN
$8.62B
$66.8M 1.54%
1,458,333
– –
DNLI icon
20
Denali Therapeutics
DNLI
$3.79B
$45.9M 1.06%
2,250,000
+250,000
+13% +$6.4M
EVH icon
21
Evolent Health
EVH
$371M
$45M 1.04%
4,000,000
+2,600,000
+186% +$45.7M
ALKS icon
22
Alkermes
ALKS
$8.11B
$43.1M 1%
1,500,000
+1,300,000
+650% +$37.4M
MYGN icon
23
Myriad Genetics
MYGN
$476M
$42.5M 0.98%
3,100,000
-850,000
-22% -$15.7M
MEDP icon
24
Medpace
MEDP
$16.3B
$41.5M 0.96%
125,000
– –
CI icon
25
Cigna
CI
$78.4B
$41.4M 0.96%
+150,000
New +$47.8M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Camber Capital Management held 43 positions worth $4.32B, up 37% from $3.15B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Camber Capital Management deployed $1.47B of net new capital in Q4 2024, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was Pfizer: 5,000,000 shares worth $133M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 80% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Zimmer Biomet, an estimated $96M trimmed.

  • Camber Capital Management's largest Q4 2024 buy was Pfizer: 5,000,000 shares worth $133M.
  • Camber Capital Management added most to Humana in Q4 2024, an estimated $121M increase.
  • Camber Capital Management's biggest Q4 2024 reduction was Zimmer Biomet, cutting an estimated $96M.
  • Camber Capital Management fully exited Select Medical in Q4 2024, selling an estimated $74.1M.
  • Camber Capital Management's ten largest holdings make up 68% of its $4.32B portfolio in Q4 2024.
  • Camber Capital Management opened 10 new positions and closed 4 in Q4 2024.
  • Camber Capital Management's portfolio value rose 37% quarter-over-quarter to $4.32B.

Based on Camber Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.